Kimberly-Clark Reports Board Changes and Compensation Updates
Ticker: KMB · Form: 8-K · Filed: Nov 13, 2024 · CIK: 55785
| Field | Detail |
|---|---|
| Company | Kimberly Clark CORP (KMB) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: KMB
TL;DR
KMB board shakeup and exec pay changes announced Nov 13.
AI Summary
Kimberly-Clark Corporation announced on November 13, 2024, changes within its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory plans for key executives.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance and compensation updates, which typically carry low risk.
Key Players & Entities
- Kimberly-Clark Corporation (company) — Registrant
- November 13, 2024 (date) — Date of Report
FAQ
What specific items are being reported under Item 5.02 of the Form 8-K?
Item 5.02 covers the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements of certain officers.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is KIMBERLY-CLARK CORPORATION.
In which state was Kimberly-Clark Corporation incorporated?
Kimberly-Clark Corporation was incorporated in Delaware.
What is the fiscal year end for Kimberly-Clark Corporation?
The fiscal year end for Kimberly-Clark Corporation is December 31.
What is the principal executive office address for Kimberly-Clark Corporation?
The address of the principal executive offices is P.O. Box 619100, Dallas, TX 75261-9100.
Filing Stats: 890 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-11-13 17:03:23
Filing Documents
- pre-20241113.htm (8-K) — 32KB
- pre-20241113_g1.jpg (GRAPHIC) — 68KB
- 0000055785-24-000098.txt ( ) — 354KB
- pre-20241113.xsd (EX-101.SCH) — 2KB
- pre-20241113_def.xml (EX-101.DEF) — 14KB
- pre-20241113_lab.xml (EX-101.LAB) — 25KB
- pre-20241113_pre.xml (EX-101.PRE) — 15KB
- pre-20241113_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. 99.1 News release issued by Kimberly-Clark Corporation on November 13, 2024. 104 The cover page of the Kimberly-Clark Corporation's Current Report on Form 8-K, formatted in iXBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KIMBERLY-CLARK CORPORATION By: /s/ Grant B. McGee Grant B. McGee Senior Vice President, General Counsel and Corporate Secretary November 13, 2024 Exhibit 99.1 Kimberly-Clark Elects Joseph Romanelli to its Board of Directors DALLAS, November 13, 2024 -- Kimberly-Clark Corporation (NYSE: KMB) today announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, USA, ("MSD") has been elected to its board of directors, effective immediately. In connection with the election, Kimberly-Clark's board size will increase from 12 to 13 directors. "Joe Romanelli is an outstanding addition to the Kimberly-Clark board of directors," said Mike Hsu, chairman and chief executive officer of Kimberly-Clark. "As we advance our Powering Care strategy, we will benefit from Joe's global leadership experience and his expertise in using leading-edge science to save and improve lives around the world." Mr. Romanelli has served as president of Human Health International for MSD, a global healthcare company that develops and manufactures medicines, vaccines, biologic therapies, and animal health products, since 2022. In this role, he oversees MSD's 75-plus markets outside of the U.S. and leads a team of 14,000 colleagues. Prior to joining MSD, Mr. Romanelli served as the chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company. Previously, he served in a variety of strategic and operational roles with increasing responsibility at MSD and Schering-Plough for 25 years. About Kimberly-Clark Kimberly-Clark (NYSE: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries. Fueled by ingenuity, creativity, and an understanding of people's most essential needs, we create pro